

## Publikační činnost Kliniky hematologie za rok 2016

### Publikace in extenso:

#### Články v časopisech s IF

1. Radocha J, Pour L, Pika T, Maisnar V, Špička I, Gregora E, Krejčí M, Minařík J, Machálková K, Straub J, Pavlíček P, **Hájek R**, Žák P. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. *Eur J Haematol.* 2016 Feb;96(2):119-27.
2. Kryukova E, Kryukov F, Hajek R. Centrosome amplification and clonal evolution in multiple myeloma: Short review. *Crit Rev Oncol Hematol.* 2016 Feb;98:116-21.
3. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, **Hájek R**, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer HH, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orłowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncol.* 2016 Jan; 17(1):27-38.
4. Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantonio G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, **Hájek R**, Boccadoro M, Palumbo A. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. *Blood.* 2016 Mar 3;127(9):1102-8.
5. **Jelinek T, Kufova Z, Hajek R**, Immunomodulatory drugs in AL amyloidosis. *Crit Rev Oncol Hematol.* 2016 Mar;99:249-60.
6. **Jelinek T, Hajek R**. Monoclonal antibodies - A new era in the treatment of multiple myeloma. *Blood Rev.* 2016 Mar;30(2):101-10.
7. Kryukov F, Nemeč P, Radocha L, Kryukova E, Okubote S, Minařík J, Stefanikova Z, Pour L, **Hájek R**. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. *J Transl Med.* 2016 May 28;14(1):150.
8. Besse L, Sedlářiková L, Gresliková H, Kupska R, Almasi M, Penka M, **Jelinek T**, Pour L, Adam Z, Kuglík P, Krejčí M, **Hájek R**, Sevciková S. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. *Eur J Haematol.* 2016 Jul;97(1):93-100.
9. Orłowski RZ, Nagler A, Sonneveld P, Bladé J, **Hájek R**, Spencer A, Robak T, Dmoszyska A, Horvath N, Špička I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A,

- Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. *Cancer*. 2016 Jul 1;122(13):2050-6.
10. Kryukov F, Kryukova E, Brozova L, **Kufova Z, Filipova J, Growkova K, Sevcikova T, Jarkovsky J, Hajek R**. Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. *Gene*. 2016 Oct 15;591(2):490-8.
  11. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, **Hájek R**, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma. *Blood*. 2016 Sep 1;128(9):1174-80
  12. Mikulasova A, Smetana J, Wayhelova M, Janyskova H, Sandecká V, **Kufova Z**, Almasi M, Jarkovsky J, Gregora E, Kessler P, Wrobel M, Walker BA, Wardell CP, Morgan GJ, **Hajek R**, Kuglik P. Genome-wide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. *Eur J Haematol*. 2016 Dec;97(6):568-575.
  13. Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova J, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, **Duras J**, Mocikova H, Mayer J, Trneny M. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. *Leuk Lymphoma*. 2016 May;57(5):1094-103.
  14. Kuliha M, Roubec M, Goldírová A, Hurtíková E, Jonszta T, Procházka V, **Gumulec J**, Herzig R, Školoudík D. Laboratory-Based Markers as Predictors of Brain Infarction During Carotid Stenting: a Prospective Study. *J Atheroscler Thromb*. 2016 Jul 1;23(7):839-47
  15. Valkova V, Jircikova J, Trnkova M, Steinerova K, Keslova P, Lanska M, **Koristek Z**, Raida L, Krejci M, Krontoradova K, Dolezal T, Benesova K, Cetkovsky P, Trneny M. The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study. *Neoplasma*. 2016 Jul 29;63(5).
  16. Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, **Hajek R**, Pour L, Willenbacher W, Greil R, Jöhrer K. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. *Oncotarget*. 2016 Nov 29;7(48):78605-78618.
  17. MIKULÁŠOVÁ, A., J. SMETANA, M. WAYHELOVÁ, H. JANYŠKOVÁ, S.A. OKUBOTE, **R. HÁJEK** a P. KUGLÍK. Whole genome amplification effect on segmental copy-number changes and copy-number neutral loss of heterozygosity analysis by oligonucleotide-based array-comparative genomic hybridization in human myeloma cell line. *International journal of clinical and experimental pathology* [online]. 2016, vol. 9, no. 7, p. 6965-6976.
  18. SMETANA, J., P. KUGLÍK, H. GREŠLÍKOVÁ, R. KUPSKÁ, P. NĚMEC, A. MIKULÁŠOVÁ, I. VALÁŠKOVÁ, J. OPPELT, M. ALMÁŠI, M. KREJČÍ, Z. ADAM, L.

- POUR a **R. HÁJEK**. Clonal cytogenetics changes in progression of multiple myeloma to extramedullary relapse and plasmocellular leukemia: a case report. *International journal of clinical and experimental pathology* [online]. 2016, vol. 9, no. 1, p. 49-60.
19. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; **TOURMALINE-MM1 Study Group**. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016 Apr 28;374(17):1621-34
20. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schechter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; **CASTOR Investigators**. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016 Aug 25;375(8):754-66.

### Články v recenzovaných časopisech

1. **Kascak M, Duras J, Navratil M, Hajek R**. Autologní transplantace kmenových bunek u Waldenströmovy makroglobulinemie, *Transfuze Hematol. Dnes* 22, 2016, No. 1, p. 28-38
2. **MUDr. Jana Fečková Mihályová, MUDr. Juraj Ďuraš, MUDr. Jana Zuchnická, MUDr. Michal Kaščák, prof. MUDr. Roman Hájek, CSc.** Ibrutinib v hematonekologii. *Klin Farmakol Farm* 2016;30(3):8-14.
3. Cetkovský, Petr, **Kořístek, Zdeněk**, Starý, Jan, Štěrba, Jaroslav, Žák, Pavel., Současnost a budoucnost alternativních zdrojů hematopoetických buněk včetně pupečnickové krve. *Perspektivy bank pupečnickové krve. Závěry Panelu expertů . Transfuze a hematologie dnes*. 2016, roč. 22, č. 3, s. 210-223.
4. Krejčí, Marta, Sedláček, Petr, Jindra, Pavel, Marková, Markéta, Faber, Edgar, Žák, Pavel, Trněný, Marek, Kozák, Tomáš, Štěrba, Jaroslav, Hájek, Roman, Büchler, Tomáš, Kuříková, Marie, Mayer, Jiří, Starý, Jan, Karas, Michal, Vítek, Antonín, Raida, Luděk, Pohlreich, David, **Kořístek, Zdeněk**, Cetkovský, Petr. Indikace k alogenním a autologním transplantacím krevetvorných buněk v ČR v roce 2016: doporučení Transplantační sekce České hematologické společnosti ČLS JEP a České onkologické společnosti ČLS JEP . *Transfuze a hematologie dnes*. 2016, roč. 22, č. 2, s. 127-150.

### Články v ostatních časopisech

1. **MUDr. Lenka Zahradová, Ph.D., MUDr. Hana Plonková, MUDr. Kristina Grácová, Prof. MUDr. Roman Hájek, CSc.** Nové inovativní léky v léčbě mnohočetného myelomu. *Remedia* 2016;26(4):224-338
2. **Tóthová E., Kafková A.** Mnohopočetný myelom: MyKE 2016, *Onkológia* 2016; 11(5):326-328.

3. Kafková A., **Tóthová E.** Ponatinib v limbe Ph-pozitívnej chronickej myelocytovej leukémii rezistentnej voči inhibítorom tyrozínkinázy 1. a 2. Generácie. Farmakoterapia 2016;6(2):154-157.
4. **Tóthová E.**, Kafková A. Aktualizácia výsledkov klinickej štúdie PACE (2016. Farmakoterapia 2016;6(2):91-92.
5. **MUDr. Jana Zuchnická, MUDr. Jana Fečková Mihályová, prof. MUDr. Roman Hájek, CSc.** Léčba starší nemocné s chronickou lymfocytární leukemií kombinací obinutuzumab a chlorambucil. Acta Medicinæ 2016;11:44-46
6. **MUDr. Jana Zuchnická, MUDr. Jana Fečková Mihályová, Prof. MUDr. Roman Hájek, CSc.** Chronická lymfocytární leukemie – současné možnosti léčby. Remedia 2016;26(5): 1-8.
7. **Tóthová E.** Tlejúci (smoldering) mnohopočetný myelom, Onkológia 2016; 11(2):94-98.
8. Kafková A., **Tóthová E.** Monoklonové protilátky v liečbe mnohopočetného myelómu. Onkológia 2016;11(5):280-284)
9. **MUDr. Michal Kaščák, Mgr. Zuzaná Kufová, Mgr. Kateřina Growková, prof. MUDr. Roman Hájek, CSc.** Waldenströmova makroglobulinémie v roce 2016: optimalizace imunochemoterapie s cílem minimalizace nežádoucích účinků. Onkológia 2016;11(5):291-295.
10. **Zahradová L.** Systémová amyloidóza. Onkológia 2016;11(6):361-364

### Knihy a kapitoly v knihách:

1. **Kořístek Z.** Odběr a zpracování kostní dřeně a periferních hematopoetických buněk pro HCT, In P. Cetkovský a kol. Transplantace kostní dřeně a periferních hematopoetických buněk. Galén 2016. ISBN 978-80-7492-267-1.
2. **Kořístek Z.** Zákonné regulace a akreditace programů HCT, In P. Cetkovský a kol. Transplantace kostní dřeně a periferních hematopoetických buněk. Galén 2016. ISBN 978-80-7492-267-1.
3. **Hájek R.** HCT v léčbě mnohočetného myelomu, In P. Cetkovský a kol. Transplantace kostní dřeně a periferních hematopoetických buněk. Galén 2016. ISBN 978-80-7492-267-1.

### Přednášky:

#### Přednášky (zahraniční konference)

1. Hájek R. Sequential treatment and modern therapies for Multiple Myeloma. Haematologic Workshop, Szczecin, Poland 1/2016
2. Hájek R. Léčebný pokrok u relabujícího mnohočetného myelomu. VIII. Bratislavské hematologické a transfuziologické dni. Bratislava, Slovak Republic, 10/2016
3. Hájek R. Pathophysiology of MM and targets for existing & future drugs and their Combinations. 6. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT, Warsaw, Poland, 2/2016

4. Hájek R. The new therapies and challenges in treating Multiple Myeloma. 5th CONGRESS OF SLOVENIAN HAEMATOLOGICAL SOCIETY. Laško, Slovenia. 4/2016
5. Hájek R. Současný význam Minimal Residual Disease u mnohočetného myelomu. Myelomové fórum 2016, Bratislava, Slovak Republic, 5/2016
6. Hájek R. - chair of the Education Session on "Multiple myeloma. 21st Congress of the European Hematology Association (EHA). Copenhagen, Denmark, 6/2016.
7. Hájek R. Do we still need alkylators in the era of IMiD's and PI's? II Międzynarodowa Konferencja Szkoleniowa "Hematologia Kliniczna i Doświadczalna" Kazimierz Dolny, Poland, 5/2016
8. Hájek R. Toward the Cure - Multiple Myeloma. 4th African Pharma Congress. Cape Town, South Africa, 6/2016
9. Hájek R. Pro & Contra-Session: „Good bye to CRAB - should we treat MM earlier ?“ and how .....FIRST AUSTRIAN MYELOMA SUMMER SCHOOL 2016. Salzburg, Austria, 7/2016
10. Hájek R Triplet Therapies for Relapsed Multiple Myeloma and the Role of Cytogenetic Testing and Risk Assessment in Treatment Selection. ANNUAL INTENSIVE DAY MEETING FOR FINNISH HAEMATOLOGISTS, 'INTENSIVE DAY WARM-UP', HELSINKI, FINLAND, 9/2016.
11. Gumulec J. Heparinem indukovaná trombocytopenie. XXIII.Slovensko-česká konferencia o hemostáze a trombóze. Martin, Slovak Republic. 5/2016
12. Kaščák M. Raritní diagnózy v hematologii. Amyloidóza a Waldenströmová makroglobulinémie, Myelomové fórum, Bratislava, Slovak Republic 5/016

### **Přednášky (tuzemská konference)**

1. Hajek R. Diagnostic methods and prognostic tools in amyloidosis. Multiple Myeloma and Amyloidosis Preceptorship, 2016, Ostrava
2. Hajek R. Case study discussion: management of amyloidosis. Multiple Myeloma and Amyloidosis Preceptorship, 2016, Ostrava
3. Hajek R. Immunomodulatory agents in multiple myeloma, SMM and amyloidosis. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2016, Ostrava
4. Hajek R. Novel agents in MM – mechanism of action. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2016, Ostrava
5. R. Hajek, Z. Kufova. Case study discussion: management of amyloidosis, Amgen Workshop: Multiple Myeloma and Amyloidosis Preceptorship, 2016

6. Roman Hájek. Introduction to multiple myeloma and other monoclonal gammopathies. Multiple Myeloma and Amyloidosis Preceptorship, 2016, Ostrava
7. Lenka Zahradova. Frontline treatment of multiple myeloma, Multiple Myeloma and Amyloidosis Preceptorship, 2016, Ostrava
8. Lenka Zahradova. Case study discussion: decision-making in frontline treatment. Multiple Myeloma and Amyloidosis Preceptorship, 2016, Ostrava
9. Roman Hájek. Treatment strategies for relapsed/refractory patients. Multiple Myeloma and Amyloidosis Preceptorship, 2016, Ostrava
10. Lenka Zahradova. Case study discussion: relapsed/refractory patients. Multiple Myeloma and Amyloidosis Preceptorship, 2016, Ostrava
11. Roman Hájek. New strategies in multiple myeloma: focus on continuous treatment and minimal residual disease. Multiple Myeloma and Amyloidosis Preceptorship, 2016, Ostrava
12. Roman Hájek. Optimal management of amyloidosis. Multiple Myeloma and Amyloidosis Preceptorship, 2016, Ostrava
13. Roman Hájek. Understanding of pathogenesis of monoclonal gammopathy. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2016, Ostrava
14. Roman Hájek. Principle of monoclonal gammopathy diagnosis. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2016, Ostrava
15. Roman Hájek. Early myeloma, high risk vs. low risk smouldering myeloma and MGUS? "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2016, Ostrava
16. Roman Hájek. Principles of modern treatment of multiple myeloma - first targets and long-term strategy. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2016, Ostrava
17. Roman Hájek. Principles of modern treatment of amyloidosis. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2015, Ostrava
18. Roman Hájek. Clinical trials in monoclonal gammopathies – overview. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2016, Ostrava
19. Kaščák Michal. What are specific diagnostic tools for IgM MGUS and MorbusWaldenström? "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2016, Ostrava
20. Kaščák Michal. Principles of modern treatment of MorbusWaldenström. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 2016, Ostrava
21. Tóthová E. Chronická myeloidní leukémie a jiné myeloproliferace, Ostrava, Pařízkovy dny 2016
22. Jelinek T. Immune checkpoint inhibitors in multiple myeloma., 11th myeloma workshop, Brno, 2016
23. Zuchnická J. Akutní infarkt myokardu – typické příznaky, netypický průběh a příčina. Ostrava, Pařízkovy dny 2016
24. Zuchnická J. Pacient s akutní leukémií – klinický obraz. Ostrava, Pařízkovy dny 2016

25. Stejskal L. Kazuistika trombocytopenie, případ Š.S. – raritní komplikace termického traumatu. Ostrava, Pařízkovy dny 2016
26. Stejskal L. Diferenciální diagnostika splenomegalie – seminář interních oborů Třinec 24.5.2016
27. Stejskal L. Diferenciální diagnostika splenomegalie – seminář pro praktické lékaře 22.9.2016
28. Kučerová Z., Richterová P. Kasuistika trombocytopenie. Ostrava, Pařízkovy dny 2016
29. Michal Kaščák, Lenka Zahradová, Roman Hájek, Waldenströмова makroglubulinémie. Novinky 2016, XIV. workshop mnohočetný myelom s mezinárodní účastí a Roční setkání České myelomové skupiny Mikulov 15.-16.4.2016
30. M.Kaščák, R.Hájek Raritní diagnózy v hematologii. Amyloidóza a Waldenströмова makroglobulinemie, Myelomové fórum, 13.5-14.05.2016 Bratislava 2016
31. M.Kaščák, R.Hájek What are specific diagnostic tools for IgM MGUS and MorbusWaldenström? Workshopu Multiple Myeloma and Amyloidosis , 14.-16.3.2016, Ostrava
32. M.Kaščák, R.Hájek Principles of modern treatment of Morbus Waldenström Workshopu Multiple Myeloma and Amyloidosis , 14.-16.3.2016, Ostrava
33. M.Kaščák, R.Hájek What are specific diagnostic tools for IgM MGUS and MorbusWaldenström? Multiple myeloma and Amyloidosis Educational Workshop 29-31 August 2016
34. M.Kaščák, R.Hájek Principles of modern treatment of Morbus Waldenström, Multiple myeloma and Amyloidosis Educational Workshop 29-31 August 2016
35. M.Kaščák, R.Hájek What are specific diagnostic tools for IgM MGUS and MorbusWaldenström? “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies” Workshop: September 12 - 14, 2016
36. M.Kaščák, R.Hájek Principles of modern treatment of Morbus Waldenström “Understanding of Modern Haematology: Focus on Monoclonal Gammopathies” Workshop: September 12 - 14, 2016
37. J. Ďuraš - Léčba starších pacientů s folikulárním lymfomem – Setkání Kooperativní lymfomové skupiny Praha 16.3.2016
38. J. Ďuraš - Lymfadenopatie pro hematoonkologa. Seminář pro praktické lékaře. Ostrava 22.9.2016
39. Maňásek V., Ďuraš J., Jelínek T. (Nový Jičín, Ostrava Výběr optimálního žilního vstupu s ohledem na specifika hematologického a hematoonkologického pacienta, Olomoucké hematologické dny 2016 – 30.5.2016
40. Ševčíková T., Growková K., Filipová J., Kufová Z., Hanusová H., Vrublová P., Kryukova E., Kryukov F., and Hájek R. Sample processing for high-throughput techniques: methodological approach. Presented at 11th Myeloma workshop; 12.-13.10.2016; Brno, Czech Republic

## Postery:

### Postery (zahraniční konference)

1. Roman Hájek, Tomas Jelinek, MD, Vladimir Maisnar, MD, PhD, Ludek Pour, Ivan Spicka, MD PhD, Jiri Minarik, MD, PhD, Evzen Gregora, MD, Petr Kessler, MD, Michal Sykora, MD, Hana Frankova, MD, Dagmar Adamova, MD, Marek Wróbel, Peter Mikula, MD, Jiri Jarkovsky, MSc, PhD, Xenia Gatopoulou, Sarka Vesela, Joris Diels, PhD, Hervé Besson, PhD, Lucie Brozova, MSc and Tetsuro Ito. Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients. ASH 2016, San Diego, USA, 12/2016
2. Leire Burgos, Diego Alignani, Juan-Jose Garces, Lourdes Ortiz, Tomas Jelinek, MD, Victor Segura, PhD, Luzalba Sanoja, Maria-Jose Calasanz, Xabier Agirre, PhD, Felipe Prosper, MD, Paula Rodriguez-Otero, MD, PhD, Rafael Rios, Joaquin Martinez-Lopez, Luis Palomera, MD, PhD, Maria Teresa Zudaire, Rafael Del Orbe, MD, Jacques J.M. van Dongen, MD, PhD, Alberto Orfao, MD, PhD, Bruno Paiva, PhD and Jesus San Miguel, MD PhD. Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs). ASH 2016, San Diego, USA, 12/2016
3. Leire Burgos, Diego Alignani, Juan-Jose Garces, Lourdes Ortiz, Tomas Jelinek, MD, Victor Segura, PhD, Luzalba Sanoja, Maria-Jose Calasanz, Xabier Agirre, PhD, Felipe Prosper, MD, Paula Rodriguez-Otero, MD, PhD, Rafael Rios, Joaquin Martinez-Lopez, Luis Palomera, MD, PhD, Maria Teresa Zudaire, Rafael Del Orbe, MD, Jacques J.M. van Dongen, MD, PhD, Alberto Orfao, MD, PhD, Bruno Paiva, PhD and Jesus San Miguel, MD PhD. High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM). ASH 2016, San Diego, USA, 12/2016
4. Laura Moreno, Aintzane Zabaleta, Diego Alignani, Marta Lasa, Patricia Maiso, PhD, Tomas Jelinek, MD, Victor Segura, PhD, Jose Antonio Delgado, Paula Rodriguez-Otero, MD, PhD, Felipe Prosper, MD, Klaus Strein, MD, PhD, Minh Diem Vu, PhD, Jesus San Miguel, MD PhD and Bruno Paiva, PhD. New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM). ASH 2016, San Diego, USA, 12/2016
5. Laura Moreno, Aintzane Zabaleta, Diego Alignani, Daniel Ajona, Marta Lasa, Patricia Maiso, PhD, Tomas Jelinek, MD, Victor Segura, PhD, Jose Antonio Delgado, Paula Rodriguez-Otero, MD, PhD, Felipe Prosper, MD, Jesus San Miguel, MD PhD and Bruno Paiva, PhD. Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38



Monoclonal Antibody Isatuximab in Multiple Myeloma. ASH 2016, San Diego, USA, 12/2016

6. Roman Hájek, Jiri Jarkovsky, MSc, PhD, Walter Bouwmeester, Maarten Treur, Lucy DeCosta, Marco Campioni, Michel Delforge, Marc S. Raab, MD, Paul Schoen, Zsolt Szabo, MD, Brozova Lucie and Sebastian Gonzalez-McQuire. Exploration of Survival Stratification of Patients with Multiple Myeloma after First Relapse Using Real World Data ASH 2016, San Diego, USA, 12/2016
7. Roman Hájek, Jiri Jarkovsky, MSc, PhD, Walter Bouwmeester, Maarten Treur, DeCosta Lucy, Marco Campioni, Michel Delforge, Marc S. Raab, MD, Paul Schoen, Zsolt Szabo, MD and Sebastian Gonzalez-McQuire. The Value of Risk Stratification Tools in Multiple Myeloma (MM) in the Real-World: Validation of the Revised- International Staging System (R-ISS) at Initiation of Treatment and Relevance of the ISS and the R-ISS for Risk Stratification in the Relapsed Setting Using Data from the Czech Registry of Monoclonal Gammopathies (RMG). ASH 2016, San Diego, USA, 12/2016
8. Jorge J. Castillo, MD, Artur J. Jurczynszyn, MD, PhD, Edvan Crusoe, MD, MsC, Jacek Czepiel, MD, Julio Davila, MD, Angela Dispenzieri, MD, Marion Eveillard, PharmD, PhD, Mark A Fiala, BS, CCRP, Irene M. Ghobrial, MD, Alessandro Gozzetti, MD, Joshua Gustine, MPH, Roman Hájek, Vânia Hungria, MD, PhD, Jiri Jarkovsky, MSc, PhD, David Jayabalan, BSMS, MSc, Jacob P. Laubach, MD, Barbara Lewicka, MD, Vladimir Maisnar, MD, PhD, Elisabeth E. Manasanch, MD, Philippe Moreau, MD, Hareth Nahi, Ruben Niesvizky, Claudia E. Paba-Prada, MD, Tomas Pika, MD, PhD, Ludek Pour, MD, PhD, John L Reagan, MD, Paul G Richardson, MD, Jatin J. Shah, MD, Ivan Spicka, MD PhD, Ravi Vij, MD, Anna Waszczuk, MD, PhD and Morie A. Gertz, MD, MACP. IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. ASH 2016, San Diego, USA, 12/2016
9. Barbara Gamberi, Miguel Hernandez, Christian Berthou, Eleni Tholouli, Elena Zamagni, Roman Hájek, Monique Minnema, Meletios Dimopoulos, Jo Caers, Niels Frost Andersen, Bjorn Andreasson, Anders Waage, MD PhD, Gerard Crotty, Elisabeth Kueenburg, Barbara Rosettani, Antonia Di Micco, Pamela Bacon and Igor Blau. European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib. ASH 2016, San Diego, USA, 12/2016
10. Jakub Radocha, MD, PhD, Vladimír Maisnar, MD, PhD, Ludek Pour, MD, PhD, Zdenek Adam, MD, PhD, Ivan Spicka, MD PhD, Jan Straub, MD, Vlastimil Scudla, prof, MD, PhD, Jiri Minarik, MD, PhD, Evzen Gregora, MD, Petr Pavlicek, MD, Hana Frankova, MD, Lenka Zahradova, MD PhD, Alexandra Jungova, MD, Michal Sykora, MD, Petr Kessler, MD, Dagmar Adamova, MD, Marek Wrobel, MD, Lenka Sedlarikova, MSc, Sabina Sevcikova, RNDr, PhD, Daniel Horinek, Ing, Jana Pelcova, MSc, Jiri Jarkovsky, MSc, PhD and Roman Hájek. Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population. ASH 2016, San Diego, USA, 12/2016

11. Roman Hájek, Jarkovsky Jiri, Bouwmeester Walter, Treur Maarten, DeCosta Lucy, Campioni Marco, Brozova Lucie and Sebastian Gonzalez-McQuire. Predictors of Overall Survival (OS) in Patients with Multiple Myeloma (MM) Initiating First- and Second-Line Treatment in the Czech Republic. ASH 2016, San Diego, USA, 12/2016
12. Davine Hofste op Bruinink, MD, MSc, Stefania Oliva, MD, Lucie Rihova, PhD, Bronno van der Holt, PhD, Milena Gilestro, BSc, Jeroen G. te Marvelde, BSc, Pavla Vsianska, MSc, Alexander Schmitz, PhD, Helle Høholt, BSc, Hans Erik Johnsen, MD DMSc, Mario Boccadoro, MD, Roman Hajek, MD, Pieter Sonneveld, MD PhD, Antonio Palumbo, MD, Paola Omedè, PhD and Vincent H.J. van der Velden, PhD. Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. ASH 2016, San Diego, USA, 12/2016
13. Lenka Sedlarikova, MSc, Barbora Gromesova, MSc, Jana Filipova, MSc, Veronika Kubaczkova, MSc, Lenka Radova, PhD, Martina Almasi, PhD, Miroslav Penka, MD, PhD, Zdenek Adam, MD, PhD, Ludek Pour, MD, PhD, Marta Krejci, MD, PhD, Sabina Sevcikova, RNDr, PhD and Roman Hajek, prof, MD, PhD. Deregulated Expression of Long Non-Coding RNAs UCA1, NEAT1 and BDNF-As in Multiple Myeloma. ASH 2016, San Diego, USA, 12/2016
14. Andrea Janikova, MD. PhD., Assoc Prof, Robert Pytlik, MD, Pavel Klener, MD, PhD, Zbynek Bortlicek, PhD, Vit Campyr, MD, PhD, Natasa Kopalova, Mgr, Katerina Benesova, MD, PhD., Michaela Hamouzova, David Belada, MD PhD, Vit Prochazka, MD, PhD, ass. prof., Jan Pirnos, MD, Juraj Duras, MD, Heidi Mocikova, M.D., Ph.D., Jiri Mayer, MD and Marek Trneny. Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry. ASH 2016, San Diego, USA, 12/2016
15. Tóthová E. Association of selected gene polymorphisms with prognosis and treatment results in follicular lymphoma patients. An International Congress on Hematologic Malignancies. New York, USA, 10/2016
16. Roman Hájek, Stuart D Russell, Alexander Lyon, Daniel Lenihan, Phillippe Moreau, Douglas Joshua, Wee-Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, Thierry Facon, Heinz Ludwig, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaidano, Vesselina Goranova-Marinova, Heidi H Gillenwater, Nehal Mohamed, Shibao Feng, Meletios Dimopoulos. A SUBSTUDY OF THE PHASE 3 ENDEAVOR STUDY: SERIAL ECHOCARDIOGRAPHIC ASSESSMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA (RMM) RECEIVING CARFILZOMIB PLUS DEXAMETHASONE OR BORTEZOMIB PLUS DEXAMETHASONE. EHA 2016, Copenhagen, Denmark, 6/2016.
17. Roman Hajek, Jiri Jarkovsky, Vladimír Maisnar, Ludek Pour, Ivan Spicka, Jiri Minařík, Evžen Gregora, Petr Kessler, Michal Sýkora, Hana Fraňková, Dagmar Adamova, Marek Wróbel, Peter Mikula, Marco Campioni, Lucy DeCosta, Maarten Treur, Sebastian

- Gonzalez-McQuire, Walter Bouwmeester. SURVIVAL AND TREATMENT PATTERNS IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA (MM) IN A REAL-WORLD SETTING. EHA 2016, Copenhagen, Denmark, 6/2016.
18. Tereza Sevcikova, Fedor Kryukov, Lucie Brozova, Jana Filipova, Zuzana Kufova, Katerina Growkova, Renata Bezdekova, Pavel Nemecek, Lucie Rihova, JiriJarkovsky, and Roman Hajek. Gene Expression Profile of Circulating Myeloma Cells Reveals CD44 and CD97 (ADGRE5) Overexpression. E-poster session presented at: 58th ASH Annual Meeting & Exposition; 3.-6.12.2016; San Diego, USA
  19. Lucie Adamusová, Zdeněk Kořístek, Jana Smejkalová, Petra Vrublová, Lukáš Grebeníček, Roman Hájek. Results of Sepax 2 validation for washing of PBSC transplants after thawing and process optimization. Poster session presented at: 42nd Annual Meeting of the European Society for Blood and Marrow transplantation; 3.-6. 4. 2016 Valencia, Spain.
  20. Kryukova E., Brožová L., Bešše L., Growková K., Sedlaříková L., Filipová J., Nekvidová J., Kufova Z., Ševčíková T., Jarkovský J., Ševčíková S., Zahradová L., Kryukov F., and Hájek R. Circulating serum miRNA profile in AL amyloidosis. Poster session presented at: 21st Congress of European Hematology Association; 9.-12.6.2016; Copenhagen, Denmark
  21. Kufova Z., Kryukova E., Brožová L., Bešše L., Growková K., Sedlaříková L., Filipová J., Nekvidová J., Ševčíková T., Grosicki S., Jurczyszyn A., Jarkovský J., Ševčíková S., Zahradová L., Kryukov F., and Hájek R. Potential novel biomarkers for diagnostics of AL amyloidosis. Poster session presented at: XV International Symposium on Amyloidosis; 3.-7.7.2016; Uppsala, Sweden
  22. Kufova Z., Januška J., Ševčíková T., Jelínek T., Kryukov F., and Hájek R. Implementation of next generation sequencing (NGS) in samples with suspected hereditary amyloidosis – first experience. Poster session presented at: XV International Symposium on Amyloidosis; 3.-7.7.2016; Uppsala, Sweden
  23. Growková K., Kufova Z., Kaščák M., Filipová J., Ševčíková T., Kryukova E., Roziaková L., Mistrík M., Barchnicka A., Grosicki S., Kryukov F., and Hájek R. Detection and long-term monitoring of somatic mutations MYD88L265P and CXCR4C1013G in Waldenström's macroglobulinemia. Poster session presented at: 9th International Workshop on Waldenström's Macroglobulinemia and Symposium on Advances in Multiple Myeloma; 5.-8.10.2016; Amsterdam, Netherlands

### **Postery (tuzemská konference)**

1. J. Ďuraš, T. Jelínek, J. Mihályová, H. Cieslarová, J. Gumulec, R. Hájek. Zkušenosti s PICC u hematoonkologických nemocných na Klinice hematoonkologie FN Ostrava. II. Mezinárodní vědeckou konferenci Problematika správného používání žilních vstupů se zaměřením na PICC. 11/2016, Praha

2. Fečková Mihályová J. Léčba rizikové CLL a postavení alogenní transplantace v éře nových inhibitorů, OHD 6/2016
3. Growková K., Filipová J., Kuřová Z., Ševčíková T., Hanusová H., Vrublová P., Kryukova E., Zahradová L., Kryukov F., and Hájek R. Lab guideline optimization for pre-processing of samples with small amount of input material in monoclonal gammopathies. Poster session presented at: XXII. Pařízkovy dny; 10.-11.3.2016; Ostrava, Czech Republic
4. Lucie Adamusová, Zdeněk Kořístek, Jana Smejkalová, Petra Vrublová, Lukáš Grebeníček, Roman Hájek. Výsledky a optimalizace procesu promytí transplantátů PBSC po rozmrazení pomocí přístroje Sepax 2. Poster session presented at: XXII. Pařízkovy dny; 10.-11.3.2016; Ostrava, Czech Republic
5. Filipová J., Growková K., Kuřová Z., Ševčíková T., Hanusová H., Vrublová P., Kryukova E., Zahradová L., Kryukov F., and Hájek R. Sample pre-processing for downstream application in AL amyloidosis. Poster session presented at: XXX. Olomoucké hematologické dny; 29.-30.5.2016; Olomouc, Czech Republic
6. Lucie Adamusová, Zdeněk Kořístek, Jana Smejkalová, Petra Vrublová, Lukáš Grebeníček, Magda Michalíková, Roman Hájek. První autologní podání promytých hematopoetických kmenových buněk (HSC) pomocí Sepax 2 pacientovi s těžkým poškozením ledvin. Poster session presented at: XXX. Olomoucké hematologické dny; 29.-30.5.2016; Olomouc, Czech Republic
7. Kuřová Z., Januška J., Ševčíková T., Jelínek T., Kryukov F., and Hájek R. Zavedení sekvenování nové generace pro pacienty se suspektní hereditární amyloidózou- první zkušenost. Poster session presented at: XX. celostátní konference DNA diagnostiky; 3.-4.11.2016; Dolní Morava, Czech Republic

### Abstrakta:

1. Lucie Rihova, PhD, Pavla Vsianska, MSc, Renata Bezdekova, MSc, Zdenek Adam, prof, MD, PhD, Miroslav Penka, prof, MD, PhD, Tomas Jelinek, MD, Sabina Sevcikova, RNDr, PhD, Ludek Pour, MD, PhD and Roman Hájek, prof, MD, PhD. Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse. ASH 2016, San Diego, USA, 12/2016 (Abstract #97664)
2. Pieter Sonneveld, MD PhD, Meral Beksac, Professor, Bronno van der Holt, PhD, Meletios A. Dimopoulos, Angelo Michele Carella, Heinz Ludwig, Christoph Driessen, MD, PhD, Ruth Wester, Roman Hajek, Sandra Croockewit, Rossella Troia, Francesca Gay, MD, Anna Maria Cafro, Luca De Rosa, G Fioritoni, MD, Ulf-Henrik Mellqvist, Hans Erik Johnsen, MD DMSc, Sonja Zweegman, MD, PhD, Ka Lung Wu, Joana Parreira, MD, Fredrik H. Schjesvold, MD, James D'Rozario, Antonio Palumbo, MD and Michele Cavo.

Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial). ASH 2016, San Diego, USA, 12/2016 Program: Oral and Poster Abstracts

3. Michele Cavo, Meral Beksac, MD, Meletios Dimopoulos, Lucia Pantani, Francesca Gay, MD, Roman Hájek, Nicoletta Testoni, Ulf-Henrik Mellqvist, Francesca Patriarca, Vittorio Montefusco, MD, Monica Galli, Hans Erik Johnsen, MD DMSc, Heinz Ludwig, Sonja Zweegman, Ruth Wester, Ka Lung Wu, Christoph Driessen, Rossella Troia, Petra Cornelisse, Bronno van der Holt, PhD, Antonio Palumbo, MD and Pieter Sonneveld. Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network. ASH 2016, San Diego, USA, 12/2016 Program: Oral and Poster Abstracts
4. Efsthathios Kastritis, MD, Xavier Leleu, Bertrand Arnulf, MD, Elena Zamagni, María Teresa Cibeira, MD, Fiona Kwok, FRACP, FRCPA, MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Roman Hajek, MD, Philippe Moreau, Arnaud Jaccard, MD, PhD, Stefan Schönland, MD, Robin Filshie, PhD FRACP FRCPA, Emmanuelle Nicolas-Virelizier, MD, Bradley Augustson, Maria-Victoria Mateos, MD, PhD, Ashutosh Wechalekar, MD, FRCPPath, Eric Hachulla, MD, PhD, Paolo Milani, MD, Meletios Dimopoulos, Jean-Paul Femand, Andrea Foli, MD, Maria Gavriatopoulou, Antonio Palumbo, MD, Pieter Sonneveld, MD PhD, Hans Erik Johnsen, MD DMSc, Giampaolo Merlini, MD and Giovanni Palladini, MD, PhD. A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. ASH 2016, San Diego, USA, 12/2016 Program: Oral and Poster Abstracts
5. Francesca Gay, MD, Mattia D'Agostino, MD, Roman Hajek, prof, MD, PhD, Sara Bringhen, MD, Concetta Conticello, MD, Gianluca Gaidano, MD, PhD, Vittorio Montefusco, Sara Pezzatti, MD, Marco Salvini, MD, Tommaso Caravita, MD, Anna Maria Cafro, MD, Michele Cavo, MD, Marina Ruggeri, Fortunato Morabito, MD, Roberto Mina, MD, Luca Baldini, MD, Prof, Giulia Benevolo, MD, Tommasina Guglielmelli, MD, Annalisa Bernardini, Roberto Foà, MD, Francesca Patriarca, MD, Massimo Offidani, MD, Roberto Ria, MD, Dina Ben Yehuda, MD, Maria Teresa Petrucci, MD, Andrew Spencer, MD, Antonio Palumbo, MD and Mario Boccadoro, MD. Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. ASH 2016, San Diego, USA, 12/2016 Program: Oral and Poster Abstracts
6. Gumulec J. Klinické aspekty diagnostiky a kontroly terapie heparinem izolované trombocytopenie. XVII. ČESKO-SLOVENSKÉ KONFERENCE LABORATORNÍ HEMATOLOGIE, SBORNÍK ABSTRAKT ISBN 978-80-906205-4-4

7. Gumulec J. Heparinem indukovaná trombocytopenie. Vaskulárna medicína. Suplement. XXIII. slovensko-česká konferencia o hemostáze a trombóze s medzinárodnou účasťou: 19. - 21. máj 2016, Martin: program a abstrakty. Bratislava: SOLEN, 2016, 8. ISSN 13380214.
8. Gumulec J. Pravidla akutní péče u pacientů na NOACs. Neurol. praxi 2016; 17(Suppl E). Valašsko-Lašské neurologické sympozium. 4-5.11.2016. Karolinka